Clinical

The phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end point.

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.

Researchers assessed overall survival outcomes in patients in France.

An expert panel navigates stigmas and barriers inhibiting patients from achieving optimal care for HIV.

Dr Adam C. Welch drives a discussion highlighting disparities in health care equity affecting patients who receive an HIV diagnosis.

New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.

Associations between intervention dosage and hospital use outcomes were observed among patients enrolled in a care management program serving individuals with complex needs.

Wanda Filer, MD, MBA, FAAFP, provides an overview of the potential outcomes for patients of all ages with RSV.

Key opinion leaders discuss ongoing clinical trials for respiratory syncytial virus vaccines.

The panel discusses potential therapy options for adults infected with respiratory syncytial virus.

The authors examined the association of diabetes with self-reported gaps in care coordination and self-reported preventable adverse events using data from a national sample of older adults.

In their final thoughts, medical experts highlight key considerations in the atopic dermatitis (AD) treatment landscape.

Amy Brennan underlines the impact of affordability and how it may be inhibiting the patient atopic dermatitis (AD) treatment process.

In this interview, Tycel Phillips, MD, associate professor of medicine, Division of Lymphoma and Bone Marrow Transplantation, City of Hope, Duarte, California, discusses the advancements that are shaping the future of B-cell lymphoma treatment, as well as access barriers.

The decreasing cost of DNA sequencing has contributed to an uptick in genomic sequencing for precision diagnostics in rare diseases.

The new classifications included several major changes and may help identify different subtypes.

It’s estimated around 20% of patients will discontinue their first course of anti–tumor necrosis factor-α (anti–TNF-α) and rates increase over time

Results are based on a study of low-dose interleukin-2 (IL-2) carried out at Dana-Farber Cancer Institute.

To the authors’ knowledge, the study is the first to include a patient with essential thrombocythemia (ET) and MPL and Type 1 calreticulin gene mutations.

Although methotrexate was linked with a higher risk of anemia, it carried risks of kidney and other serious infections similar to those of biologics.

Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.

The prevalence of high metabolism scores for visceral fat, especially among sensitive populations, may be associated with a heightened asthma risk, according to one study.

The study, wrote the researchers, offers insight into emerging and uncommon complications following chimeric antigen receptor (CAR) T-cell therapy.

Unmet needs include both improved myasthenia gravis treatments as well as a way to monitor progression of the disease, said James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.

The approval makes the drug Europe’s first and only interleukin (IL)-17A inhibitor approved for the condition.